Advances in Clinical and Experimental Medicine

Adv Clin Exp Med
Impact Factor (IF) – 1.227
Index Copernicus (ICV 2018) – 157.72
MNiSW – 40
Average rejection rate – 84.38%
ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download PDF

Advances in Clinical and Experimental Medicine

2019, vol. 28, nr 9, September, p. 1171–1177

doi: 10.17219/acem/103799

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Creative Commons BY-NC-ND 3.0 Open Access

Melatonin protects against streptozotocin-induced diabetic cardiomyopathy through the mammalian target of rapamycin (mTOR) signaling pathway

Yasemin Behram Kandemir1,A,B,C,D, Veysel Tosun2,B,C,D, Ünal Güntekin3,E,F

1 Department of Anatomy, Faculty of Medicine, Harran University, Şanlıurfa, Turkey

2 Department of Cardiology, Şanlıurfa Education and Research Hospital, Turkey

3 Department of Cardiology, Faculty of Medicine, Akdeniz University, Antalya, Turkey

Abstract

Background. Several studies demonstrated that the overexpression of mammalian target of rapamycin (mTOR) signaling protein is associated with cardiomyopathy. However, the effect of mTOR on the heart in hyperglycemic condition is still controversial.
Objectives. We aimed to investigate the expression of mTOR and antioxidant enzyme activity in cardiac hypertrophy in rats with streptozotocin-induced diabetes mellitus (DM), and the effects of the melatonin on diabetic cardiomyopathy (DCM).
Material and Methods. Forty male Wistar rats were used as the experimental animals. The rats were divided into 4 groups (10 animals in each): group 1 (control group), group 2 (ethanol vehicle group), group 3 (iatrogenically DM-induced group), and group 4 (group given melatonin after iatrogenical DM induction). Streptozotocin was injected intraperitoneally to group 3 and 4 to induce experimental type 1 DM. Melatonin was injected intraperitoneally at a dose of 50 mg/kg/day for 56 days to group 4. We investigated expression of mTOR levels in heart muscle fibers of all groups. Laboratory analysis and transthoracic echocardiography were performed.
Results. Melatonin increased the activity of superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPx), which were reduced due to hyperglycemia. The mTOR expression levels were significantly higher in group 3 (DM group) compared with controls, whereas melatonin treatment significantly decreased the levels of mTOR expression in group 4 (melatonin + DM group). Diabetic rats developed myocardial hypertrophy with preserved cardiac function.
Conclusion. Cardioprotective effect of melatonin may reduce damages caused by DM in the heart muscle fibers through the mTOR signaling pathway.

Key words

melatonin, diabetic cardiomyopathy, mammalian target of rapamycin

References (34)

  1. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322(22):1561–1566.
  2. Marwick TH, Ritchie R, Shaw JE, Kaye D. Implications of underlying mechanisms for the recognition and management of diabetic cardiomyopathy. J Am Coll Cardiol. 2018;71(3):339–351.
  3. Tsushima K, Bugger H, Wende AR, et al. Mitochondrial reactive oxygen species in lipotoxic hearts induces post-translational modifications of AKAP121, DRP1 and OPA1 that promote mitochondrial fission. Circ Res. 2018;122(1):58–73.
  4. Liu W, Ruiz-Velasco A, Wang S, et al. Metabolic stress-induced cardiomyopathy is caused by mitochondrial dysfunction due to attenuated Erk5 signaling. Nat Commun. 2017;8(1):494.
  5. Zhang Y, Sun X, Icli B, Feinberg MW. Emerging roles for microRNAs in diabetic microvascular disease: Novel targets for therapy. Endocr Rev. 2017;38(2):145–168.
  6. Shimobayashi M, Hall MN. Making new contacts: the mTOR network in metabolism and signaling crosstalk. Nat Rev Mol Cell Biol. 2014;15(3):155.
  7. Shende P, Plaisance I, Morandi C, et al. Cardiac raptor ablation impairs adaptive hypertrophy, alters metabolic gene expression, and causes heart failure in mice. Circulation. 2011;123(10):1073–1082.
  8. Aoyagi T, Kusakari Y, Xiao CY, et al. Cardiac mTOR protects the heart against ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. 2012;303(1):H75–H85.
  9. Huang Z, Zhuang X, Xie C, et al. Exogenous hydrogen sulfide attenuates high glucose-induced cardiotoxicity by inhibiting NLRP3 inflammasome activation by suppressing TLR4/NF-κB pathway in H9c2 cells. Cell Physiol Biochem. 2016;40(6):1578–1590.
  10. Patel V, Upaganlawar A, Zalawadia R, Balaraman R. Cardioprotective effect of melatonin against isoproterenol induced myocardial infarction in rats: A biochemical, electrocardiographic and histoarchitectural evaluation. Eur J Pharmacol. 2010;644(1–3):160–168.
  11. Anderson EJ, Kypson AP, Rodriguez E, Anderson CA, Lehr EJ, Neufer PD. Substrate-specific derangements in mitochondrial metabolism and redox balance in the atrium of the type 2 diabetic human heart. J Am Coll Cardiol. 2009;54(20):1891–1898.
  12. Braunwald E. Biomarkers in heart failure. N Engl J Med. 2008;358(20):2148–2159.
  13. Zhao F, Liu ZQ, Wu D. Antioxidative effect of melatonin on DNA and erythrocytes against free-radical-induced oxidation. Chem Phys ­Lipids. 2008;151(2):77–84.
  14. Lin XJ, Mei GP, Liu J, et al. Therapeutic effects of melatonin on heatstroke-induced multiple organ dysfunction syndrome in rats. J ­Pineal Res. 2011;50(4):436–444.
  15. Liu LF, Qin Q, Qian ZH, et al. Protective effects of melatonin on ischemia-reperfusion induced myocardial damage and hemodynamic recovery in rats. Eur Rev Med Pharmacol Sci. 2014;18(23):3681–3686.
  16. Hoyer DP, Korkmaz Y, Grönke S, et al. Differential expression of protein kinase C isoforms in coronary arteries of diabetic mice lacking the G-protein Gα11. Cardiovasc Diabetol. 2010;9:93.
  17. Reuter H, Seuthe K, Korkmaz Y, et al. The G protein Gα11 is essential for hypertrophic signaling in diabetic myocardium. Int J Cardiol. 2013;167(4):1476–1485.
  18. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation. 1977;55(4):613–618.
  19. Korkmaz Y, Lang H, Beikler T, et al. Irreversible inflammation is associated with decreased levels of the α1-, β1-, and α2-subunits of sGC in human odontoblasts. J Dent Res. 2011;90(4):517–522.
  20. Kaya Y, Sarıkcıoğlu L, Aslan M, et al. Comparison of the beneficial effect of melatonin on recovery after cut and crush sciatic nerve injury: a combined study using functional, electrophysiological, biochemical, and electron microscopic analyses. Childs Nerv Syst. 2013;29(3):389–401.
  21. Misra HP, Fridovich I. The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem. 1972;247(10):3170–3175.
  22. Ziegler DM, Kehrer JP. Oxygen radicals and drugs: In vitro measurements. Methods Enzymol. 1990;186:621–626.
  23. Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med. 1967;70(1):158–169.
  24. Wasowicz W, Neve J, Peretz A. Optimized steps in fluorometric determination of thiobarbituric acid-reactive substances in serum: Importance of extraction pH and influence of sample preservation and storage. Clin Chem. 1993;39(12):2522–2526.
  25. Rydén L, Grant PJ, Anker SD, et al; Authors/Task Force Members. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 2013;34(39):3035–3087.
  26. Jia G, DeMarco VG, Sowers JR. Insulin resistance and hyperinsulinemia in diabetic cardiomyopathy. Nat Rev Endocrinol. 2016;12(3):144–153.
  27. Pei Z, Deng Q, Babcock SA, He EY, Ren J, Zhang Y. Inhibition of advanced glycation endproduct (AGE) rescues against streptozotocin-induced diabetic cardiomyopathy: Role of autophagy and ER stress. Toxicol Lett. 2018;284:10–20.
  28. Suhara T, Baba Y, Shimada BK, Higa JK, Matsui T. The mTOR signaling pathway in myocardial dysfunction in type 2 diabetes mellitus. Curr Diab Rep. 2017;17(6):38.
  29. Zhang P, Xu X, Hu X, Van Deel ED, Zhu G, Chen Y. Inducible nitric oxide synthase deficiency protects the heart from systolic overload-induced ventricular hypertrophy and congestive heart failure. Circ Res. 2007;100(7):1089–1098.
  30. Shen YQ, Guerra-Librero A, Fernandez-Gil BI, et al. Combination of melatonin and rapamycin for head and neck cancer therapy: Suppression of AKT/mTOR pathway activation, and activation of mitophagy and apoptosis via mitochondrial function regulation. J Pineal Res. 2018;63(3). https://doi.org/10.1111/jpi.12461
  31. Baydas G, Canatan H, Turkoglu A. Comparative analysis of the protective effects of melatonin and vitamin E on streptozocin-induced diabetes mellitus. J Pineal Res. 2002;32(4):225–230.
  32. Ohta Y, Kongo-Nishimura M, Matsura T, Yamada K, Kitagawa A, Kishi­kawa T. Melatonin prevents disruption of hepatic reactive oxygen species metabolism in rats treated with carbon tetrachloride. J Pineal Res. 2004;36(1):10–17.
  33. Sailaja Devi MM, Suresh Y, Das UN. Preservation of the antioxidant status in chemically induced diabetes mellitus by melatonin. J ­Pineal Res. 2000;29(2):108–115.
  34. Song E, Jahng JW, Chong LP, et al. Lipocalin-2 induces NLRP3 inflammasome activation via HMGB1 induced TLR4 signaling in heart tissue of mice under pressure overload challenge. Am J Transl Res. 2017;9(6):2723–2735.